Invasive Fungal Infection Treatment Market Size, Share, Industry, Forecast and outlook (2026-2033)

Invasive Fungal Infection Treatment Market Size

The global invasive fungal infection treatment market was valued at US$11.49 billion in 2025 and is projected to reach US$15.84 billion by 2033, growing at a CAGR of 4.1% during the forecast period 2026–2033.

Invasive fungal infection (IFI) is one of the most common nosocomial infections and may result in invasive diseases in patients with various underlying diseases or other host factors. Invasive Fungal Diseases (IFD) are frequent infectious complications of hematopoietic stem cell transplantation.

Invasive Fungal Infections (IFIs) arise when fungi invade the body's deep tissues or organs.  Invasive fungal infections have the potential to be fatal, in contrast to superficial fungal infections, which only affect the skin, hair, or nails. Directed antifungal treatment is used for patients with documented fungal disease. 

Invasive Fungal Infection Treatment Market Scope

For more details on this report – Request for Sample

Invasive Fungal Infection Treatment Market Dynamics: Drivers & Restraints

Rising drug developments 

Increasing drug developments against invasive fungal infections are expected to drive market growth during the forecast period. A large number of individuals are being affected by fungal infections and need effective drugs. Rising drug development increases the demand for new products and also serves the patients who are in need. 

Several pharmaceutical companies are introducing a wide variety of treatment options that could treat invasive fungal infections. For instance, in September 2023, BDR Pharmaceutical launched the generic antifungal drug Zisavel (isavuconazole) for the treatment of infections like invasive aspergillosis and mucormycosis.

Additionally, in April 2023, Cidara Therapeutics and Melinta Therapeutics received U.S. FDA approval for Rezzayo (rezafungin for injection). This new medication is for the treatment and prevention of candidemia and invasive candidiasis in adults who have limited or no alternative treatment options.

Also, on January 29, 2024, Cidara Therapeutics, Inc. received the United Kingdom (U.K.) Medicines and Healthcare Products Regulatory Agency (MHRA) approval for REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults. Thus, the above factors are expected to drive market growth during the forecast period.

Consequences of immunosuppressive treatment  

Antifungal activity of some immunosuppressive agents can lead to harmful microbiota changes and the selection of environmental species or isolates resistant to these drugs. Additionally, drug-drug interactions and genetic determinants of the patient might lead to suboptimal levels of drug accumulation and toxicity. Thus, the above factors are expected to hamper the market growth.

Invasive Fungal Infection Treatment Market Segmentation Analysis

The global invasive fungal infection treatment market is segmented based on disease type, drug type, distribution channel, and region.

The triazoles segment is expected to dominate the market share

The triazoles segment is expected to dominate the market growth during the forecast period, this is due to the effectiveness of these drugs over invasive fungal infections. Triazoles perform effectively against many of the fungi that cause IFIs, such as Aspergillus, Candida, and some molds.  Because of this, they provide a flexible first treatment option while medical professionals determine the exact type of fungus. Triazoles often have fewer adverse effects and a better safety profile than certain other antifungal groups. 

For individuals with impaired immune systems who might already be coping with other medical conditions, this is crucial. Triazoles come in several forms, such as oral suspensions, intravenous solutions, tablets, and capsules. This makes it possible to use various treatment strategies based on the patient's state and the infection's severity. Triazoles have been used to treat IFIs for a long time. Thus, the above factors are expected to drive the market growth. 

The growing number of alternative products is also expected to drive the segment growth. Pharmaceutical companies are increasingly providing a variety of triazole drugs which could help in the expansion of the segment growth. 

For instance, in July 2021, Cadila Pharmaceuticals launched a new triazole antifungal drug Posaconazole, which is effective against a wide range of invasive fungal diseases. The drug has also been recommended as a second-line treatment for Mucormycosis or black fungus as it is commonly known. Thus, the above factors are expected to hold the segment in the dominant position. 

Invasive Fungal Infection Treatment Market Geographical Share

North America is expected to hold a significant position in the invasive fungal infection treatment market share

North America is expected to hold a dominant position in the invasive fungal infection treatment market due to the high prevalence of invasive fungal infection, and rising public awareness of invasive fungal diseases are some of the factors expected to boost the market in the forecast period.

For instance, according to the Centers for Disease Control & Prevention in 2024, it stated that candidemia is one of the most common bloodstream infections in the United States. An estimated 25,000 cases of candidemia occur in the United States each year.

Additionally, people get histoplasmosis in certain areas in the United States, particularly around the Mississippi and Ohio River valleys. Around 60-90% of people living in that area are exposed to Histoplasma in their lifetime. The increasing prevalence of invasive fungal infections in the region is expected to increase the demand for the drugs available. Thus, the above factors are expected to hold the region in the dominant position during the forecast period. 

Invasive Fungal Infection Treatment Market Segmentation

By Disease Type

• Candidemia and Invasive Candidiasis
• Intra-abdominal Candidiasis
• Cryptococcal Meningitis
• Esophageal Candidiasis
• Histoplasmosis Acute Pulmonary
• Invasive Aspergillosis
• Invasive Rhinosinusitis
• Mucormycosis
• Others

By Drug Type

• Polyenes
  • Amphotericin B deoxycholate
  • Lipid formulation amphotericin B.
  • Others
• Triazoles
  • Fluconazole
  • Itraconazole
  • Posaconazole
  • Voriconazole
  • Others
• Echinocandins
  • Anidulafungin
  • Caspofungin
  • Micafungin
  • Others
• Flucytosine
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa  

Invasive Fungal Infection Treatment Market Competitive Landscape

The major global players in the market include Merck & Co., Inc., Fresenius Kabi AG, Cidara Therapeutics Inc., Xellia Pharmaceuticals, Aark Pharmaceuticals., Intelicure Lifesciences, Taj Life Sciences Pvt Ltd, Angle Bio Pharma, Cadila Pharmaceuticals Limited and Stanex Drugs & Chemicals Pvt. Ltd. among others.

Invasive Fungal Infection Treatment Recent Developments

• September 2026 – SCYNEXIS secures major BARDA funding for invasive fungal infection treatment
  SCYNEXIS was awarded a BARDA contract of up to US$214 million to advance SCY-247, a next-generation triterpenoid antifungal being developed for the treatment of invasive candidiasis and prevention of invasive fungal diseases. The funding is expected to support advancement of the program toward Phase 2 development.
• July 2026 – FDA expands REZZAYO indication for pediatric patients
  The U.S. FDA expanded the approved use of REZZAYO (rezafungin) to include adults and pediatric patients 12 years of age and older with limited or no alternative options for the treatment of candidemia and invasive candidiasis. The expansion broadens the potential patient population for once-weekly echinocandin therapy.
• March 2026 – New antifungal development targets invasive mould infections
  A 2026 review of emerging antifungals highlighted continued clinical development of fosmanogepix, olorofim, opelconazole, rezafungin, and ibrexafungerp for difficult-to-treat invasive mould infections, reflecting growing efforts to address resistance and limited treatment options.
• January 2026 – Basilea and Prokaryotics collaborate on broad-spectrum antifungal
  Basilea Pharmaceutica and Prokaryotics entered a collaboration to develop a first-in-class broad-spectrum antifungal for severe invasive infections. The program targets infections caused by Candida, Aspergillus, and rare moulds, with the collaboration intended to advance a clinical candidate into further development.
• November 2025 – Olorofim demonstrates potential for difficult-to-treat invasive fungal disease
  Phase 2b clinical data published in The Lancet Infectious Diseases evaluated olorofim in patients with few or no therapeutic options for invasive fungal disease and probable invasive pulmonary aspergillosis. The study supports continued development of olorofim as a potential option for resistant or difficult-to-treat fungal infections.
• 2025 – Development pipeline expands for invasive candidiasis
  Research published in 2025 highlighted continued development of novel agents including fosmanogepix, rezafungin, ibrexafungerp, BAL2062, and ATI-2307 for invasive candidiasis, driven by increasing resistance to established azoles, echinocandins, and polyenes and the spread of multidrug-resistant Candida auris.
• 2025 – Novel antifungal therapies gain attention for resistant infections
  Recent clinical research has increasingly focused on agents with new mechanisms of action, including olorofim and fosmanogepix, as potential alternatives for invasive fungal infections where conventional antifungal options are limited by resistance, toxicity, drug interactions, or route-of-administration challenges.

Why Purchase the Report?

• To visualize the global invasive fungal infection treatment market segmentation based on disease type, drug type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of invasive fungal infection treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global invasive fungal infection treatment market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies